Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $151.00 target price on the stock. BTIG Research’s price objective points to a potential upside of 139.00% from the stock’s current price.

Other research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Barclays upped their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Wedbush set a $165.00 price objective on Oruka Therapeutics in a research report on Monday, April 27th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Finally, Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, April 30th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

Oruka Therapeutics Trading Down 2.3%

NASDAQ:ORKA opened at $63.18 on Thursday. Oruka Therapeutics has a 1 year low of $8.91 and a 1 year high of $91.00. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -33.97 and a beta of -0.20. The stock has a 50-day moving average price of $54.01 and a two-hundred day moving average price of $38.92.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. Sell-side analysts forecast that Oruka Therapeutics will post -2.2 earnings per share for the current year.

Insider Activity

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total value of $462,840.00. Following the sale, the insider owned 33,377 shares in the company, valued at $2,206,887.24. The trade was a 17.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,765 shares of company stock worth $1,089,745 in the last quarter. 23.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ORKA. Legal & General Group Plc bought a new stake in Oruka Therapeutics during the second quarter worth about $28,000. BNP Paribas Financial Markets raised its stake in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada raised its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC bought a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in Oruka Therapeutics in the third quarter valued at approximately $39,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.